about
Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions.Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cellsGvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies.Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia.Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years.Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype.Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction.The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation.Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease.Cutaneous macrophage infiltration in acute GvHD.Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adultsShort-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adultsImpacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donorsLymphoid blast crisis of chronic myelogenous leukemia occurring more than 11 years after receiving an allogeneic bone marrow transplant for chronic myelogenous leukemia in myeloid blast crisis at onsetA prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignanciesChimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapseSuccessful unrelated cord blood transplantation for adult acquired aplastic anemia using reduced intensity conditioning without ATGAnalysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioningProspective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndromeCorrection to: Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioningComparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies
P50
Q33577929-37F458CC-BB9A-4F50-93C4-E4011FECA541Q35651760-3F7AB4CD-AC3C-4A94-93E3-64629B01D3B0Q38730402-175F31F4-CA4D-4530-99E8-17A1E0011166Q38927497-AB707D9A-2507-41D1-B384-DC31D5BFC180Q39110465-DD8950E5-824C-4E74-B6DE-5B32C9F7F6CAQ40261051-58D613BD-142D-4CE9-8223-3A7152DB4867Q40421080-DFFB8C54-7D43-47DB-A2AC-6D8DC17DB067Q40883726-219BBCA4-379D-4AA8-9E1F-176DD15D092DQ41603853-A6B26A5B-E4EF-4220-9DD2-4343E79FFCFFQ46683630-455F25D7-E8BC-4725-8EC1-B95DBAF4EEC6Q47375318-6A757D41-419E-444D-87E0-BA257BDD6A0BQ47438165-24702993-7CFE-4F8A-B67A-2B31606B9206Q48051318-195AC507-A3FA-4C81-8BA7-1ACD60EFC937Q48337197-CCDC154A-58C9-4E25-9C70-011001CD20CAQ50601549-B7B4FEF5-D36D-4D6B-99BC-80D248C82EC2Q52944429-5DF527F4-DB9A-4770-A697-6C95D5F86AAFQ57918596-F58FA607-2AB0-4B61-9E64-AFBE3EFD20FEQ57918775-4251B300-75DB-4A46-9EFE-B25D7EE236EFQ60913025-AA96E05D-6FE5-4C08-8208-81D478619630Q73089019-058784C3-FF64-4C5D-87AE-9DCA1F3321DBQ83357079-D98DB145-AFF6-4224-8DB8-E6BEE1E84047Q86727021-FA13F393-5FEB-4E4E-96CC-F21565F9C7C4Q87214364-8010A7BB-76A6-4661-92D0-C7FEFE7E64F6Q90296087-2DCF53CA-B584-4227-A632-00DE61BB09F4Q90590314-21B52CC5-2ED5-4A98-AFBE-EA61F903E1B5Q91481150-42651466-FCA7-4673-B0CC-7124E2BE8A46Q95641630-F2AC4B21-C197-400C-A750-5EFC01E159EE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Seitaro Terakura
@ast
Seitaro Terakura
@en
Seitaro Terakura
@es
Seitaro Terakura
@nl
type
label
Seitaro Terakura
@ast
Seitaro Terakura
@en
Seitaro Terakura
@es
Seitaro Terakura
@nl
prefLabel
Seitaro Terakura
@ast
Seitaro Terakura
@en
Seitaro Terakura
@es
Seitaro Terakura
@nl
P106
P31
P496
0000-0002-1194-8046